Skip to main content
Nature Communications logoLink to Nature Communications
. 2018 Feb 22;9:779. doi: 10.1038/s41467-018-02995-6

Single-molecule theory of enzymatic inhibition

Tal Robin 1, Shlomi Reuveni 1,2,, Michael Urbakh 1
PMCID: PMC5823943  PMID: 29472579

Abstract

The classical theory of enzymatic inhibition takes a deterministic, bulk based approach to quantitatively describe how inhibitors affect the progression of enzymatic reactions. Catalysis at the single-enzyme level is, however, inherently stochastic which could lead to strong deviations from classical predictions. To explore this, we take the single-enzyme perspective and rebuild the theory of enzymatic inhibition from the bottom up. We find that accounting for multi-conformational enzyme structure and intrinsic randomness should strongly change our view on the uncompetitive and mixed modes of inhibition. There, stochastic fluctuations at the single-enzyme level could make inhibitors act as activators; and we state—in terms of experimentally measurable quantities—a mathematical condition for the emergence of this surprising phenomenon. Our findings could explain why certain molecules that inhibit enzymatic activity when substrate concentrations are high, elicit a non-monotonic dose response when substrate concentrations are low.


Single molecule approaches demonstrated that enzymatic catalysis is stochastic which could lead to deviations from classical predictions. Here authors rebuild the theory of enzymatic inhibition to show that stochastic fluctuations on the single enzyme level could make inhibitors act as activators.

Introduction

Enzymes spin the wheel of life by catalyzing a myriad of chemical reactions central to the growth, development, and metabolism of all living organisms1,2. Without enzymes, essential processes would progress so slowly that life would virtually grind to a halt; and some enzymatic reactions are so critical that inhibiting them may result in death. Enzymatic inhibitors could thus be potent poisons3,4 but could also be used as antibiotics5,6 and drugs to treat other forms of disease7,8. Inhibitors have additional commercial uses9,10, but the fundamental principles which govern their interaction with enzymes are not always understood in full, and have yet ceased to fascinate those interested in the basic aspects of enzyme science. The canonical description of enzymatic inhibition received much exposure1,2,11, but even at the level of bulk reactions its many limitations have already been pointed out12. Moreover, and despite rapid advancements in the study of uninhibited enzymatic reactions on the single-molecule level, the study of inhibited reactions has barely made progress in this direction and is still based, by and large, on what is known in bulk.

Single-molecule approaches revolutionized our understanding of enzymatic catalysis13,14. Early work demonstrated that at the single molecule level, enzymatic catalysis is inherently stochastic15,16, and that one often needs to go beyond the common Markovian description to adequately account for the observed kinetics1720. Universal aspects of stochastic enzyme kinetics, including the widespread applicability of the Michaelis–Menten equation and its insensitivity to microscopic details, were discovered2127; and the study of enzymatic reactions under force has shed new light on the mechanics of the catalytic process2832.

In light of the above, it is somewhat surprising that single-molecule studies of inhibited enzymatic reactions trail behind and are just starting to emerge3337. Specifically, a single-molecule theory of enzymatic inhibition, and in particular one that takes into account non-Markovian effects, is still lacking. Stochastic, single-molecule, descriptions of inhibited enzymatic catalysis can be found, but these are oftentimes based on simple kinetic schemes that fail to capture the multi-conformational nature of enzymes, or properly account for intrinsic randomness at the microscopic level. From a mathematical perspective, these kinetic schemes are usually built as Markov chains, and while one could expand them to account for increased complexity this then also compels the introduction of many additional parameters. These tend to complicate analysis, and also make it extremely difficult to discover universal principles by generalizing from simple examples. Here, we circumvent these problems by avoiding the Markov chain formulation to develop a non-Markovian theory of enzymatic inhibition at the single-enzyme level.

The simplest Markovian description of enzymatic inhibition at the single-molecule level assumes that the completion times of various processes involved in the enzymatic reaction come from exponential distributions (rates depend on process). However, and as discussed above, single-molecule experiments suggest that enzymatic catalysis is often non-Markovian. The exponential distribution should then be replaced, but the correct underlying distributions are usually unknown and guessing them is certainly no solution to this problem. Instead, we choose not to guess, allowing for catalysis, and other, times involved in the reaction to come from general, i.e., completely unspecified, distributions. This is the central and most important difference between our approach and the classical one. Rather than first, and often wrongly, assuming that all distributions are exponential (or come from some other prespecified statistics that is dictated by the structure of the Markov-chain used), and then carrying out the analysis, we show that analysis can be carried out even when underlying time distributions are treated as unknowns. Moreover, since we do not try and guess which features of the underlying distributions are important, we also do not run into the risk of being mistaken in that guess. In other words, relevant parameters emerge from our theory as output rather than being fed into it as input.

An approach similar to the one described above has previously allowed us to revisit the fundamentals of uninhibited enzymatic reactions, and show that the role of unbinding in these must be more complicated than initially perceived38. This then facilitated advancements in the theory of restarted first-passage-time processes3941 as it can be shown that the mathematical description of such processes is virtually identical to that of enzymatic catalysis at the single-molecule level. Below, we extend our approach to treat inhibited enzymatic reactions. Conclusions drawn from our analysis are then compared against conventional wisdom to predict cases where stochastic fluctuations at the level of the single enzyme would inevitably lead to a strong departure from the classically anticipated behavior.

Results

The classical theory of enzymatic inhibition

The classical theory of enzymatic inhibition considers the effect of molecular inhibitors on enzymatic reactions in the bulk, and focuses on three canonical modes of inhibition (Fig. 1). In this theory, the concentrations of enzyme, substrate, inhibitor, and the various complexes formed are taken to be continuous quantities and differential equations are written to describe their evolution in time. Assuming that inhibitor molecules can bind either to the free enzyme, E, or the enzyme substrate complex, ES, as in the case of mixed inhibition (Fig. 1), and that all complexes reach fast equilibrium (the quasi-steady-state approximation), it can be shown that the per enzyme turnover rate, kturn, of an inhibited enzymatic reaction obeys11

1kturn=Km1+IKEIvmax1S+1+IKESIvmax. 1

Fig. 1.

Fig. 1

The three canonical modes of enzymatic inhibition. From left to right: competitive, uncompetitive, and mixed inhibition. Rates govern transitions between the different states: free enzyme (E), enzyme–substrate complex (ES), enzyme–inhibitor complex (EI), enzyme–substrate–inhibitor complex (ESI), and the (E + P) state which represents the end of a turnover cycle

Here, [S] and [I], respectively, denote the concentrations of substrate and inhibitor, vmax is the maximal, per enzyme, turnover rate attained at an excess of substrate and no inhibition, and Km is the so-called Michaelis constant, i.e., the substrate concentration required for the rate of an uninhibited reaction to reach half its maximal value. Values for the kinetic parameters, Km and vmax, usually lie in the rage of 10−2–106 μm and 10−2–105 s−1, respectively42; and in all subsequent examples parameters were chosen to comply with these typical values.

The parameters KEI and KESI denote the equilibrium constants related with reversible association of the inhibitor to form the molecular complexes EI and ESI, respectively. In the classical theory, the constants, Km,KEI, and KESI can all be expressed using rates of elementary processes (see Fig. 1) to get Km=(koff+kcat)kon, KEI=koffEIkonEI, and KESI=koffESIkonESI, where kon and koff are the rates at which the substrate binds and unbinds the enzyme, and konEI konESI and koffEI koffESI are the rates at which the inhibitor binds and unbinds the enzyme (enzyme–substrate complex). Finally, note that turnover rates for the special cases of competitive and uncompetitive inhibition can be respectively deduced from Eq. (1) by taking the KESI and KEI limits there.

The kinetic schemes described in Fig. 1 also serve as a starting point for a single-molecule theory of enzymatic inhibition. This theory is fundamentally different from the bulk one as it aims to describe the stochastic act of a single enzyme embedded in a “sea” of substrate and inhibitor molecules. However, the main observable here is once again the turnover rate, kturn, which is defined as the mean number of product molecules generated by a single enzyme per unit time. Equivalently, this rate can also be defined as kturn1Tturn, where the average turnover time Tturn is simply the mean time elapsing between successive product formation events. Interpreting the kinetic schemes in Fig. 1 as Markov Chains which govern the state-to-state transitions of a single enzyme, Eq. (1) can once again be shown to hold (Supplementary Methods).

Beyond the classical theory

The kinetic schemes presented in Fig. (1) do not account for multiple kinetics states which are often part of the reaction. For example, it is often necessary to discriminate between different enzyme–substrate complexes, but this could be done in a multitude of ways (Fig. 2 left) and the effect of inhibition should then be worked out on a case-by-case basis. This could work well when relevant states and transition rates can be determined experimentally, but doing so is often not possible technically or simply too laborious. Indeed, in the overwhelming majority of cases the number of kinetic intermediates and the manner in which they interconvert is simply unknown. There is thus a dire need for a description that will effectively take these intermediates into account even when information about them is partial or completely missing. Such description would also be useful when trying to generalize lessons learned from the analysis of simple case studies of enzymatic inhibition.

Fig. 2.

Fig. 2

A non-Markovian reaction scheme can replace infinitely many Markovian ones. Kinetic intermediates and multiple reaction pathways could complicate the description of a reaction or various parts of it. When all intermediates and rates are known, these complications could, in principle, be addressed on a case-by-case basis. Alternatively, one could account for the non-Markovian nature of transitions between coarse-grained states by allowing for generally, rather than exponentially, distributed transition times. The main advantage of this approach is that it allows for progress to be made even when the underlying reaction schemes are not known in full, i.e., in the absence of perfect information

Generic reaction schemes could be built by retaining the same state space as in the classical approach (Fig. 1) while replacing the all so familiar transition rates with generally distributed transition times. This is done in order to account for the coarse-grained nature of states, allowing for a concise description of complex reaction schemes. The time it takes to complete a transition between two states is then characterized by a generic probability density function (PDF), e.g., fTcatt for the catalysis time, Tcat, which governs the transition between the ES and E + P states above (Fig. 2 right). Applied to all other transitions, an infinitely large collection of reactions schemes could then be analyzed collectively.

Competitive inhibition at the single-enzyme level

To concretely exemplify the approach proposed above, we consider a generic, not necessarily Markovian, scheme for competitive inhibition at the single-enzyme level (Fig. 3). As usual in this mode of inhibition, the inhibitor can bind reversibly to the enzyme to form an enzyme–inhibitor complex which in turn prevents substrate binding and product formation. However, and in contrast to the Markovian approach, here we do not assume that the catalysis time Tcat is taken from an exponential distribution with rate kcat, but rather let this time come from an arbitrary distribution. Since the enzyme is single but the substrate and inhibitor are present in Avogadro numbers, we assume that the binding times Ton and TonEI are taken from exponential distributions with rates kon[S] and konEI[I] correspondingly, but the distributions of the off times Toff and ToffEI are once again left unspecified. We then find that the turnover rate of a single enzyme obeys (Supplementary Methods)

1kturn=Km1+IKEIvmax1S+1vmax. 2

Fig. 3.

Fig. 3

A generic scheme for competitive inhibition at the single-enzyme level. Transition rates have been replaced with generally distributed transition times to generalize the Markovian scheme in Fig. 1

Note that despite the fact that it is much more general, Eq. (2) shows the exact same dependencies on the substrate and inhibitor concentrations as in the classical theory (Eq. (1) in the limit KESI). This result is non-trivial, and turns out to hold irrespective of the mechanisms which govern the processes of catalysis and unbinding. However, and in contrast to Eq. (1), the constants KEI, vmax, and Km, which enter Eq. (2), can no longer be expressed in terms of simple rates, and are rather given by (Supplementary Methods): KEI=ToffEIkonEI-1, vmax= PrTcat<ToffWES0, and Km=konWES0-1. Here, ToffEI is the mean life time of the EI state (inhibitor unbinding time), PrTcat<Toff is the probability that catalysis occurs prior to substrate unbinding, and WES0=minTcat,Toff is the mean life time of the ES state (time spent in that state). Concluding, we see that while microscopic details of the reaction do enter Eq. (2), they only do so to determine various effective constants. The functional dependencies of the turnover rate on [S] and [I] are insensitive to these details, and are in this sense completely universal.

Uncompetitive inhibition at the single-enzyme level

We now turn to employ the same type of analysis to uncompetitive inhibition (Fig. 4). Interestingly, the situation here is very different from the competitive case analyzed above, and strong deviations from the classical behavior are observed. To show this, we follow a path similar to that taken above and obtain a generalized equation for the turnover rate of a single enzyme in the presence of uncompetitive inhibition (Supplementary Methods):

1kturn=KmvmaxAIS+1+IKESIBIvmax, 3

where KESI=ToffESIkonESI-1. Equation (3) should be compared to Eq. (1) in the limit KEI, and we once again see that both exhibit the same characteristic 1/[S] dependence. The dependence on inhibitor concentration is, however, different from that in Eq. (1) as Eq. (3) also includes two additional factors, AI and BI, whose emergence is a direct result of non-Markovian stochastic fluctuations at the single-enzyme level. AI and BI could be understood in terms of average life times and transition probabilities (Methods), but are otherwise complicated functions of [I]. We nevertheless note that A0=B0=1 always; and that in the Markovian case, i.e., when the schemes presented in Figs. 4 and 1 (middle) coincide, AI=BI=1 for all [I]. Equation (3) then reduces to Eq. (1) in the limit KEI, but in all other cases analyzed this is no longer true. In particular, Eq. (3) predicts that the classical, Markovian, theory of uncompetitive inhibition will inevitably break down when catalysis times come from a non-exponential distribution.

Fig. 4.

Fig. 4

A generic scheme for uncompetitive inhibition at the single-enzyme level. Transition rates have once again been replaced with generally distributed transition times to generalize the Markovian scheme in Fig. 1

Breakdown of classical theory for uncompetitive inhibition

To demonstrate the breakdown of the classical theory with a simple concrete example, we will now consider a special case of the kinetic scheme illustrated in Fig. 4. Namely, we take fTcatt=pkcat1 exp-kcat1t+1-pkcat2 exp-kcat2t, with 0p1, for the PDF of the catalysis time Tcat. We thus slightly generalize the classical scheme in Fig. 1 (middle) by taking fTcatt to be a mixture of two exponential densities (rather than a single exponential), but all other transitions times are still taken from exponential distributions. This form of fTcatt can be shown to arise when analyzing in detail a “two-state” model where the binding of a substrate to an enzyme can occur in one of two ways, with probabilities p and (1 − p), respectively, each leading to a different enzyme–substrate complex (ES1 or ES2) equipped with a distinct catalytic rate (kcat1 or kcat2). This description is equivalent to that given here (Supplementary Methods), and we therefore refer to fTcatt above as that associated with the “two state” model.

Analyzing the two-state model, we find AI and BI to be monotonically decreasing functions of [I] (See Fig. 5a & SI for explicit expressions). This is true as long as kcat1kcat2 and 0<p<1, and means that AI,BI1 for all [I]. When the inhibitor concentrations are low, these deviations from unity are linear in [I]; and for high inhibitor concentrations, both AI and BI eventually plateau at a certain level. Since this level could be much lower than unity, the variation in AI and BI may strongly affect the turnover rate in Eq. (3). Consider, for example, the limit of very high substrate concentration and note that we then have kturn-1[S]1+IKESIBIvmax. Any deviation from the classical linear relation between kturn-1 and [I] is then because B(I) is not a constant (Fig. 5b), and could thus be interpreted as a measurable telltale sign of non-Markovian kinetics.

Fig. 5.

Fig. 5

Breakdown of the classical theory for uncompetitive inhibition. a In solid blue, AI and BI from Eq. (3) for the two-state model (main text). Here, p=0.1,kcat1=50ms-1, kcat2=0.5ms-1, and all other reaction times are taken from exponential distributions with koff=2.3ms-1,kon=0.1μMms-1, and konESI=3μMms-1. The observed behavior should be compared to that obtained for kcat1=kcat2 (dashed green line). The latter case coincides with the classical reaction scheme in Fig. 1 (middle), and gives AI=BI=1 for all [I]. b The normalized inverse turnover rate vmaxkturn-1from Eq. (3) vs. [I] in the limit of saturating substrate concentration. As in a, the dashed green line is drawn for the degenerate case kcat1=kcat2, where BI=1, and a linear behavior should (and is) observed. In contrast, the solid blue line is drawn for the two-state model with parameters as in a, and one could clearly observe strong deviations from linearity. This characteristic signature of non-Markovian kinetics is directly measurable. c The turnover rate (normalized by its value in the absence of inhibition) vs. [I] for the two-state model with three different sets of parameters: (i) kcat1=kcat2=0.1ms-1 (dashed green); (ii) kcat1=10ms-1, kcat2=0.5ms-1 (dash-dot orange); and (iii) kcat1=10ms-1, kcat2=0.1ms-1 (solid blue). In all three cases, p = 0.1 and other parameters are specified in the SI. In sharp contrast to what is predicted by the classical theory, we observe that turnover may exhibit a non-monotonic dependence on inhibitor concentration. d The turnover rate, normalized by its value in the absence of inhibition, vs. [I] for three different distributions of the catalysis time: Log-normal (dashed green), Weibull (solid blue), and Gamma (dash-dot orange), all with the same mean and variance (see Supplementary Figure 1 for details). The non-monotonic behavior of kturnkturn0 indicates the breakdown of the classical theory

The most important consequence of the fact that non-exponential catalysis times render AI and BI dependent on inhibitor concentration is perhaps the emergence of inhibitor–activator duality. This phenomenon is illustrated in Fig. 5c where we plot the turnover rate from Eq. (3) for the two-state model. The classical theory predicts that turnover should always decrease monotonically with inhibitor concentration, but here we find that this is not always the case. Specifically, we observe that for certain parameter choices (particularly when kcat1kcat2, but also when differences between catalytic rates are not as drastic), turnover could increase with inhibitor concertation in a certain concentration range. This non-intuitive behavior is most pronounced at low-to-moderate inhibitor concentrations, and we see that at high inhibitor concentrations—where AI and BI are close to their asymptotic values—normal behavior is recovered (increasing inhibitor concertation lowers the turnover rate).

Our findings above demonstrate that depending on its concentration, and the inner workings of the enzyme, a molecule could act either as an inhibitor or as an activator—despite the fact that its binding always results in utter and complete shutdown of enzymatic catalysis. One way to understand this, still within the framework of the two-state model, is to realize that while the binding of such a molecule prevents product formation, it could also act as an effective switch between fast and slow catalytic states when these exist. Consider, for example, a scenario where one catalytic state is characterized by a rate that is much higher than that of the other (kcat1kcat2). This time scale separation allows for a scenario where inhibitor binding is not frequent enough to interrupt catalysis when it proceeds through the fast catalytic pathway (hence the need for low-to-moderate inhibitor concentrations), but frequent enough so as to stop catalysis when it proceeds through the slow catalytic pathway. After the inhibitor unbinds, the enzyme could return to either of the catalytic states, potentially switching from slow to fast. This type of inhibitor-induced switching greatly facilitates turnover.

The emergence of inhibitor–activator duality is not unique to the two-state model, but rather a generic phenomenon whose origin we trace to stochastic fluctuations at the single-enzyme level. Depending on the enzyme, its conformations and the way they interconvert, a multitude of catalysis time distributions may arise. However, since these stem from multiple transitions between enzymatic states, the resulting catalysis time distributions would always be non-exponential and render AI and BI inhibitor concentration dependent. This would in turn lead to the breakdown of the classical theory. To demonstrate this, we plot the turnover rate from Eq. (3) for catalysis time distributions other than the one considered so far (Fig. 5d). In all cases, we find that within a certain concertation range the presence of an uncompetitive “inhibitor” surprisingly acts to facilitate enzymatic activity. Numerical simulations further support these conclusions (Supplementary Figure S1).

A general criterion for inhibitor–activator duality

The net effect resulting from the presence of an uncompetitive inhibitor also depends on substrate concentration as is demonstrated in Figs. 6a, b where we dissect the {[I],1/[S]} plane into three, qualitatively distinct, phases. As before, we use the two-state model to illustrate that as inhibitor concentrations increase an activator–inhibitor transition may take place. However, it can now be seen that even within this simple, two-state, toy model the manner in which the activator–inhibitor transition unfolds depends on the concentration of the substrate (Fig. 6a). Moreover, in some cases a transition does not occur at all, or only occurs when substrate concentrations are low enough (Figs. 6b, c). Therefore, a general criterion for the emergence of inhibitor–activator duality is required.

Fig. 6.

Fig. 6

The emergence of inhibitor–activator duality depends on substrate concentration. a, b Phase diagrammatic representation of enzymatic turnover for two different instances of the two-state model. Here, activation is the phase where turnover is higher than its value in the absence of inhibition (i.e., when [I] = 0), and any increase in inhibitor concentration increases turnover further; transition is the phase where turnover is still higher than its value in the absence of inhibition, but where further increase in inhibitor concentration results in a decrease of the turnover rate; and inhibition is the phase where turnover is lower than its value in the absence of inhibition, and any increase in inhibitor concentration decreases turnover further still. Keeping substrate concentration fixed, and varying the concentration of the inhibitor, turnover attains a maximum when crossing the line which separates the activation and transition phases, and re-attains its value at [I] = 0 when crossing the line which separates the transition and inhibition phases. Plots were made with the following parameters: kcat1=50ms-1, kcat2=0.5ms-1, p=0.1,kon=0.2μMms-1,konESI=30μMms-1, koffESI=50ms-1 and two different values of koff (indicated in the top left corner of each panel). c Lateral cross-sections through b showing the turnover rate, normalized by its value in the absence of inhibition, as a function of [I]. The activation phase in b corresponds to the ascending branch of the curves in c, whereas the transition and inhibition phases correspond to the part of the descending branch of the curves which respectively lies above, and below, unity. Substrate concentrations, corresponding to where cross-sections in b were taken, are indicated next to each curve

Enzymatic reactions may involve many intermediate states and reaction pathways, and these could be different, or markedly more complex, than the two-state model we have analyzed above for illustration purposes. This bedazzling variety that enzymes display seems to hinder further progress as additional case studies usually need to be analyzed one at a time. However, the approach developed herein allows us to treat an infinite collection of reaction schemes in a joint and unified manner to determine the effect resulting from the introduction of an uncompetitive inhibitor. Analyzing the generic reaction scheme in Fig. 4, we find that a general criterion asserting the emergence of inhibitor–activator duality (i.e., asserting that dkturnd[I]I=0>0) can be written in terms of experimentally measurable quantities (Methods). A slightly simplified version of this criterion is discussed below.

When substrate binding and unbinding are Markovian processes with rates kon[S] and koff, respectively, but with inhibitor unbinding and catalysis times still allowed to come from arbitrarily distributions, we find that inhibitor–activator duality will be observed whenever (Methods, Supplementary Methods)

ToffESI<12CVWES02-11vmax1+koffkonS. 4

Here, ToffESI, which stands on the left-hand side for the mean life time of the ESI complex, is the only quantity in this inequality that relates to the kinetics of the inhibited enzyme. On the right-hand side, CVWES0 stands for the coefficient of variation (standard deviation over mean) associated with the stochastic life time of the ES complex in the absence of inhibition, and all other quantities are defined as they were immediately after Eq. 2. And so, despite the infinitely many degrees of freedom we have allowed for by leaving the distributions of inhibitor unbinding and catalysis times unspecified, predictions coming from our theory could still be tested on any enzyme of interest simply by measuring means and variances (rather than full distributions) of certain stochastic times associated with the reaction at the single enzyme level. This important feature of our theory carries over to the more general condition for the emergence of inhibitor–activator duality (Methods).

It should be noted that the criterion in Eq. (4) can only be fulfilled when CVWES0>1 since ToffESI is always positive. The coefficient of variation CVWES0 is a dimensionless measure for the dispersion of the distribution governing the stochastic life time of the ES state in the absence of inhibition. The more dispersed (wide) this distribution is the larger CVWES0 and vice versa. In the classical theory, the Markovian formulation implies that time spent at the ES state is exponentially distributed (Supplementary Methods). This means that the standard deviation and mean of this time are equal, i.e., CVWES0=1. In this case, and whenever the life time distribution is narrower than the exponential, inhibitor–activator duality will not be observed. Broader life time distributions with CVWES0>1 are expected for enzymes with alternative kinetic pathways19,25; and the condition in Eq. (4) will then hold as long as substrate concentrations are low enough. Moreover, if ToffESIvmax<12CVWES02-1, inhibitor–activator duality will be observed regardless of substrate concentration.

Mixed inhibition at the single-enzyme level

Before concluding, we note that the mixed mode of inhibition is subject to the same type of analysis applied above. In this case, we find (Supplementary Methods)

1kturn=Km1+IKEIvmaxA([I])S+1+IKESIB([I])vmax, 5

and a criterion analogous to Eqs. (4) and (11) in Methods is also obtained (Supplementary Methods). In fact, all of the results in this paper could be derived by starting with Eq. (5) (Supplementary Methods), which generalizes and replaces Eq. (1) to describe enzymatic inhibition at the single-enzyme level. Specifically, note that the structure of Eq. (5), and that of Eqs. (2) and (3) as special cases, casts doubt on the ability of classical methods, e.g., that of Lineweaver and Burk43, to reliably discriminate between different modes of enzymatic inhibition, and suggests that these methods be revised. Finally, we note that while the framework considered herein allows for arbitrary, rather than exponentially, distributed transition times between kinetic states, it still retains the common assumption (also used in the stochastic derivation of Eq. (1)) that the system “forgets” the state of origin after leaving it (In this sense, the approach presented in this paper could be said to be semi-Markovian.). Accounting for memory of past states could be important in certain cases, but the incorporation of a general form of such memory into the framework presented herein currently seems to be out of reach. Progress in this direction is an important future challenge and is anticipated to advance both theory and practice.

Discussion

How would the average rate at which an enzyme converts substrate into product change in the presence of a molecule whose binding to the enzyme completely shuts down its ability to catalyze? As we have shown, the answer to this question is not as simple and straightforward as it seems and curiously depends on the mode of inhibition, the molecular inner workings of the enzyme, and on a delicate interplay between substrate and inhibitor concentrations. The classical theory of inhibition provides no clue to this, but the single-enzyme approach taken herein shows that there are cases where the presence of a molecule could result in an increase of the turnover rate—even though its binding to the enzyme always results in utter and complete shutdown of enzymatic catalysis. Notably, this is not because some conformations of the enzyme–inhibitor complex are inhibitory and others excitatory or due to an interaction with some additional molecule/s44,45 (also see “inhibition paradox”12), but rather because catalysis in the absence of any external modifier is non-Markovian. In other words, multiple enzyme conformations result in non-exponential transitions between coarse-grained “states” and this, surprisingly, is already enough to produce the effect. This surprising finding not only exposes fundamental flaws in our current understanding of enzymatic inhibition, but also has direct practical implications as inhibitors are in widespread commercial use.

Take for example DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester), a compound tested and verified to act as an inhibitor of the enzyme γ-secretase. Developed and researched for over a decade, this once promising treatment of Alzheimer’s disease was eventually abandoned as it was discovered that when administered at low concentrations, and when substrate concentrations were also low, it acted as an activator4649. More awareness to the issue of inhibitor–activator duality would have surely resulted in earlier discovery of this biphasic response, saving precious time, money, and human effort.

Additional examples where inhibitor–activator duality was experimentally observed include the effects of such drugs as valinomycin, SL-verapamil, and colchicine on Pgp ATPase activity50,51, and the effect of ADP on ATP hydrolysis by GroEL52. As in the case of DAPT, the qualitative nature of the phenomenon and its features are similar to those predicted by our theory, but lack of single-molecule measurements prevents us from unambiguously concluding that the mechanism we describe is indeed the one at play. Regardless, we have hereby shown that inhibitor–activator duality is inherent to the uncompetitive and mixed modes of inhibition, and that it is expected to naturally arise due to stochastic fluctuations occurring at the level of the single enzyme. Equation (4) and its generalizations then suggest that the effect, if sought for, could be observed in enzymes exhibiting multi-conformational, non-Markovian, kinetics from the kind that has already been documented in the past1719.

Methods

Definition of AI and BI in Eqs. (3) and (5)

AI and BI are defined using two auxiliary functions

f~Ms=0e-stKmkonF¯Tcat(t)F¯Toff(t)dt 6

and

f~Ps=0e-stKmkonvmaxfTcat(t)F¯Toff(t)dt. 7

Here, Km, kon, and vmax are defined as they were right after Eq. (2) in the main text, F¯Tcat(t)=tfTcat(t)dt, and F¯Toff(t)=tfToff(t)dt. It can then be shown that (Supplementary Methods)

AI=1-konESIIKmkonf~MkonESIIf~PkonESII=1-WESTonESIPrTcat<Toff,TonESIPrTcat<Toff 8

and

BI=f~MkonESI[I]f~PkonESI[I]=WES PrTcat<ToffWES0 PrTcat<Toff,TonESI, 9

where WES0=minTcat,Toff and WES=minTcat,Toff,TonESI are correspondingly the mean life times of the ES complex with and without inhibition, and Pr(…) denotes the probability for the occurrence of a specified event.

Probabilistic derivation of Eq. (4)

When will the introduction of an uncompetitive inhibitor increase the turnover rate? Consider the difference between a scenario where inhibitor molecules are not present, and a scenario where they are present at exceedingly low concentrations. Any interaction between the ES complex and an inhibitor molecule would then be very rare but will eventually happen at some point in time. In what follows, we try to determine what will be the effect this interaction has on the average time taken to compete an enzymatic reaction cycle.

An ESI complex will be formed after the inhibitor binds. It then takes the inhibitor ToffESI units of time, on average, to unbind, and for the enzyme another Tturn0-Ton units of time to form a product after having just returned to the ES state. Here, the mean turnover time in the absence of inhibition, Tturn0=1kturn0=Kmvmax1S+1vmax, was used since inhibitor concentrations were assumed to be exceedingly low. This allows us to safely neglect the probability the enzyme encounters an inhibitor again within the remaining span of the turnover cycle, and one then only needs to note that the mean substrate binding time Ton was subtracted from Tturn0 because the reaction continues from the ES state rather than starts completely anew. In total, a product will then be formed, on average, after Tremain1=ToffESI+Tturn0-Ton units of time.

Suppose now that instead of having the inhibitor bind the ES complex as described above, the reaction would have simply carried on uninterruptedly from that point onward, i.e., as it would in the absence of inhibition. How much time would it then take it to complete? To answer this, we observe that the inhibitor encountered the ES complex at a random point in time, as opposed to immediately after its formation. Having already spent some amount of time at the ES state, the mean time remaining before the system exits this state need not necessarily be identical to the mean life time, WES0, of a freshly formed ES complex in the absence of inhibition. Indeed, the time we require here is the mean residual life time of the ES complex, i.e., starting from the random point in time at which it encountered the inhibitor and onward. A key result in renewal theory then asserts that, when averaged over all possible encounter times, the mean residual life time is given by 12WES0+12σ2WES0WES053, where σ2WES0 denotes the variance in WES0. This time could be larger, or smaller, than the mean life time WES0, and the two are equal only when σ2WES0=WES02—as happens, for example, in the case of the exponential distribution.

After the system exits the ES state two things could happen. If a product is formed the reaction there ends. Otherwise, the enzyme reverts back to its free state, and the reaction takes, on average, another Tturn0 units of time to complete. When the enzyme first enters the ES state the probability that a product is formed is PrTcat<Toff. What is, however, the probability that a product is formed from an ES complex that is first observed at some random point in time as in the scenario described above? Looking at the total time an enzyme spends at the ES state across many turnover cycles, this probability should coincide with the relative time fraction taken by ES visits which end in product formation, and this is given by PrTcat<ToffWES0Tcat<ToffWES0= PrTcat<ToffWES0ESE+PWES0, with WES0ESE+P standing for the average time spent at the ES state given that a product was formed thereafter. Summing the contributions above, we see that when the reaction is left to proceed in an uninterrupted manner a product will be formed, on average, after Tremain0=12WES0+12σ2WES0WES0+Tturn01- PrTcat<ToffWES0ESE+PWES0 units of time.

Concluding, we observe that for the introduction of an inhibitor to facilitate turnover one must have Tremain0>Tremain1, or equivalently

ToffESI<Ton+WES021+σ2WES0WES02-Tturn0PrTcat<ToffWES0ESE+PWES0. 10

Recalling that Ton=kon[S]-1, vmax= PrTcat<ToffWES0, and Km=konWES0-1, the condition in Eq. (10) (emergence of inhibitor–activator duality) can be rearranged and shown equivalent to

ToffESIWES0ratioofmeanlifetimes<12CVWES02-1contributionfromstatisticalfluctuationsinlifetimeofEScomplex+1-WES0ESE+PWES0contributionfrombiasinbreakdownofEScomplexSkm+SfractionoftimespentatESnoinhibition. 11

Once again, we turn attention to the fact that the condition in Eq. (11) only involves means and variances (rather than full distributions or higher moments) of stochastic times associated with the reaction at the single-molecule level, and that all terms in this equation are experimentally measurable. Equation (4) in the main text follows from Eq. (11) by further assuming that the time for substrate unbinding is exponentially distributed with rate koff (Supplementary Methods). An alternative derivation of Eq. (11) is given in Supplementary Methods.

Data availability

Data supporting the findings of this manuscript are available from the corresponding author upon reasonable request.

Electronic supplementary material

Peer Review File (329.8KB, pdf)

Acknowledgements

We gratefully acknowledge support from the German-Israeli Project Cooperation Program (DIP). S.R. gratefully acknowledges support from the James S. McDonnell Foundation and the Azrieli Foundation; and would also like to thank Johan Paulsson and the Department of Systems Biology at Harvard Medical School for their support and hospitality.

Author contributions

T.R., S.R., and M.U. conceived the work, derived the results, and wrote the paper.

Competing interests

The authors declare no competing finanical interests.

Footnotes

Electronic supplementary material

Supplementary Information accompanies this paper at 10.1038/s41467-018-02995-6.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Berg, J. M., Tymoczko, J. L., Gatto, G. J. & Stryer, L. Biochemistry 8th edn (Freeman, W. H., New York, NY, USA, 2015).
  • 2.Nelson, D. L. & Cox, M. M. Lehninger Principles of Biochemistry 7th ed. (Freeman, W.H., New York, NY, USA, 2017).
  • 3.Vetter J. Toxins of Amanita phalloides. Toxicon. 1998;36:13–24. doi: 10.1016/S0041-0101(97)00074-3. [DOI] [PubMed] [Google Scholar]
  • 4.Holmes CFB, Maynes JT, Perreault KR, Dawson JF, James MNG. Molecular enzymology underlying regulation of protein phosphatase-1 by natural toxins. Curr. Med. Chem. 2002;9:1981–1989. doi: 10.2174/0929867023368827. [DOI] [PubMed] [Google Scholar]
  • 5.Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics. Nat. Rev. Microbiol. 2005;3:870–881. doi: 10.1038/nrmicro1265. [DOI] [PubMed] [Google Scholar]
  • 6.Drawz SM, Bonomo RA. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 2010;23:160–201. doi: 10.1128/CMR.00037-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Endo A. The discovery & development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992;33:1569–1582. [PubMed] [Google Scholar]
  • 8.Wlodawer A, Vondrasek J. Inhibitors of hiv-1 protease: a major success of structure-assisted drug design 1. Annu. Rev. Biophys. Biomol. Struct. 1998;27:249–284. doi: 10.1146/annurev.biophys.27.1.249. [DOI] [PubMed] [Google Scholar]
  • 9.Duke SO. Overview of herbicide mechanisms of action. Environ. Health Perspect. 1990;87:263. doi: 10.1289/ehp.9087263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tan S, Evans R, Singh B. Herbicidal inhibitors of amino acid biosynthesis and herbicide-tolerant crops. Amino Acids. 2006;30:195–204. doi: 10.1007/s00726-005-0254-1. [DOI] [PubMed] [Google Scholar]
  • 11.House, J. E. Principles of Chemical Kinetics (Academic Press, Burlington, MA, USA, 2007).
  • 12.Baici A. Kinetics of Enzyme-Modifier Interactions: Selected Topics in the Theory and Diagnosis of Inhibition and Activation Mechanisms. Vienna: Springer; 2015. [Google Scholar]
  • 13.Claessen VI, et al. Single-biomolecule kinetics: the art of studying a single enzyme. Annu. Rev. Anal. Chem. 2010;3:319–340. doi: 10.1146/annurev.anchem.111808.073638. [DOI] [PubMed] [Google Scholar]
  • 14.Van Oijen AM. Single-molecule approaches to characterizing kinetics of biomolecular interactions. Curr. Opin. Biotechnol. 2011;22:75–80. doi: 10.1016/j.copbio.2010.10.002. [DOI] [PubMed] [Google Scholar]
  • 15.Funatsu T, Harada Y, Tokunaga M, Saito K, Yanagida T. Imaging of single fluorescent molecules and individual ATP turnovers by single myosin molecules in aqueous solution. Nature. 1995;374:555–559. doi: 10.1038/374555a0. [DOI] [PubMed] [Google Scholar]
  • 16.Lu HP, Xun L, Xie XS. Single-molecule enzymatic dynamics. Science. 1998;282:1877–1882. doi: 10.1126/science.282.5395.1877. [DOI] [PubMed] [Google Scholar]
  • 17.Edman L, Rigler R. Memory landscapes of single-enzyme molecules. Proc. Natl Acad. Sci. USA. 2000;97:8266–8271. doi: 10.1073/pnas.130589397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Flomenbom O, et al. Stretched exponential decay and correlations in the catalytic activity of fluctuating single lipase molecules. Proc. Natl Acad. Sci. USA. 2005;102:2368–2372. doi: 10.1073/pnas.0409039102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.English BP, et al. Ever-fluctuating single enzyme molecules: Michaelis-Menten equation revisited. Nat. Chem. Biol. 2006;2:87–94. doi: 10.1038/nchembio759. [DOI] [PubMed] [Google Scholar]
  • 20.Lerch HP, Mikhailov AS, Hess B. Conformational-relaxation models of single-enzyme kinetics. Proc. Natl Acad. Sci. USA. 2002;99:15410–15415. doi: 10.1073/pnas.232376799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Min W, et al. When does the Michaelis-Menten equation hold for fluctuating enzymes? J. Phys. Chem. B. 2006;110:20093–20097. doi: 10.1021/jp065187g. [DOI] [PubMed] [Google Scholar]
  • 22.Moffitt JR, Chemla YR, Bustamante C. Mechanistic constraints from the substrate concentration dependence of enzymatic fluctuations. Proc. Natl Acad. Sci. USA. 2010;107:15739–15744. doi: 10.1073/pnas.1006997107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Wu J, Cao J. Generalized Michaelis–Menten equation for conformation‐modulated monomeric enzymes. Single-Molecule. Biophys. Exp. Theory. 2011;146:329–365. [Google Scholar]
  • 24.Chaudhury S, Cao J, Sinitsyn NA. Universality of Poisson indicator and Fano factor of transport event statistics in ion channels and enzyme kinetics. J. Phys. Chem. B. 2013;117:503–509. doi: 10.1021/jp3096659. [DOI] [PubMed] [Google Scholar]
  • 25.Moffitt JR, Bustamante C. Extracting signal from noise: kinetic mechanisms from a Michaelis–Menten‐like expression for enzymatic fluctuations. FEBS J. 2014;281:498–517. doi: 10.1111/febs.12545. [DOI] [PubMed] [Google Scholar]
  • 26.Barato AC, Seifert U. Skewness and kurtosis in statistical kinetics. Phys. Rev. Lett. 2015;115:188103. doi: 10.1103/PhysRevLett.115.188103. [DOI] [PubMed] [Google Scholar]
  • 27.Barato AC, Seifert U. Universal bound on the Fano factor in enzyme kinetics. J. Phys. Chem. B. 2015;119:6555–6561. doi: 10.1021/acs.jpcb.5b01918. [DOI] [PubMed] [Google Scholar]
  • 28.Wiita AP, et al. Probing the chemistry of thioredoxin catalysis with force. Nature. 2007;450:124–127. doi: 10.1038/nature06231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Lomholt MA, Urbakh M, Metzler R, Klafter J. Manipulating single enzymes by an external harmonic force. Phys. Rev. Lett. 2007;98:168302. doi: 10.1103/PhysRevLett.98.168302. [DOI] [PubMed] [Google Scholar]
  • 30.Gumpp H, et al. Triggering enzymatic activity with force. Nano Lett. 2009;9:3290–3295. doi: 10.1021/nl9015705. [DOI] [PubMed] [Google Scholar]
  • 31.Alegre-Cebollada J, Perez-Jimenez R, Kosuri P, Fernandez JM. Single-molecule force spectroscopy approach to enzyme catalysis. J. Biol. Chem. 2010;285:18961–18966. doi: 10.1074/jbc.R109.011932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Puchner EM, Gaub HE. Single-molecule mechanoenzymatics. Annu. Rev. Biophys. 2012;41:497–518. doi: 10.1146/annurev-biophys-050511-102301. [DOI] [PubMed] [Google Scholar]
  • 33.Gorris HH, Rissin DM, Walt DR. Stochastic inhibitor release and binding from single-enzyme molecules. Proc. Natl Acad. Sci. USA. 2007;104:17680–17685. doi: 10.1073/pnas.0705411104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Piwonski HM, Goomanovsky M, Bensimon D, Horovitz A, Haran G. Allosteric inhibition of individual enzyme molecules trapped in lipid vesicles. Proc. Natl Acad. Sci. USA. 2012;109:E1437–E1443. doi: 10.1073/pnas.1116670109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chaudhury S. Poisson indicator and fano factor for probing dynamic disorder in single-molecule enzyme inhibition kinetics. J. Phys. Chem. B. 2014;118:10405–10412. doi: 10.1021/jp506141v. [DOI] [PubMed] [Google Scholar]
  • 36.Saha S, Sinha A, Dua A. Single-molecule enzyme kinetics in the presence of inhibitors. J. Chem. Phys. 2012;137:045102. doi: 10.1063/1.4737634. [DOI] [PubMed] [Google Scholar]
  • 37.Pelz B, Žoldák G, Zeller F, Zacharias M, Rief M. Subnanometre enzyme mechanics probed by single-molecule force spectroscopy. Nat. Commun. 2016;7:10848. doi: 10.1038/ncomms10848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Reuveni S, Urbakh M, Klafter J. Role of substrate unbinding in Michaelis–Menten enzymatic reactions. Proc. Natl Acad. Sci. USA. 2014;111:4391–4396. doi: 10.1073/pnas.1318122111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Rotbart T, Reuveni S, Urbakh M. Michaelis-Menten reaction scheme as a unified approach towards the optimal restart problem. Phys. Rev. E. 2015;92:060101. doi: 10.1103/PhysRevE.92.060101. [DOI] [PubMed] [Google Scholar]
  • 40.Reuveni S. Optimal stochastic restart renders fluctuations in first passage times universal. Phys. Rev. Lett. 2016;116:170601. doi: 10.1103/PhysRevLett.116.170601. [DOI] [PubMed] [Google Scholar]
  • 41.Pal A, Reuveni S. First passage under restart. Phys. Rev. Lett. 2017;118:030603. doi: 10.1103/PhysRevLett.118.030603. [DOI] [PubMed] [Google Scholar]
  • 42.Bar-Even A, et al. The moderately efficient enzyme: evolutionary and physicochemical trends shaping enzyme parameters. Biochemistry. 2011;50:4402–4410. doi: 10.1021/bi2002289. [DOI] [PubMed] [Google Scholar]
  • 43.Lineweaver H, Burk D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 1934;56:658–666. doi: 10.1021/ja01318a036. [DOI] [Google Scholar]
  • 44.Schenker P, Baici A. Simultaneous interaction of enzymes with two modifiers: reappraisal of kinetic models and new paradigms. J. Theor. Biol. 2009;261:318–329. doi: 10.1016/j.jtbi.2009.07.033. [DOI] [PubMed] [Google Scholar]
  • 45.Schenker P, Baici A. Paradoxical interactions between modifiers and elastase‐2. Febs. J. 2010;277:2486–2495. doi: 10.1111/j.1742-4658.2010.07663.x. [DOI] [PubMed] [Google Scholar]
  • 46.Lanz TA, et al. Concentration-dependent modulation of amyloid-β in vivo and in vitro using the γ-secretase inhibitor, LY-450139. J. Pharmacol. Exp. Ther. 2006;319:924–933. doi: 10.1124/jpet.106.110700. [DOI] [PubMed] [Google Scholar]
  • 47.Burton CR, et al. The amyloid-β rise and γ-secretase inhibitor potency depend on the level of substrate expression. J. Biol. Chem. 2008;283:22992–23003. doi: 10.1074/jbc.M804175200. [DOI] [PubMed] [Google Scholar]
  • 48.Svedružić ŽM, Popović K, Šendula-Jengić V. Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease. PLoS. ONE. 2013;8:e50759. doi: 10.1371/journal.pone.0050759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Walsh R. Are improper kinetic models hampering drug development? Peer J. 2014;2:e649. doi: 10.7717/peerj.649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Al-Shawi MK, Polar MK, Omote H, Figler RA. Transition state analysis of the coupling of drug transport to ATP hydrolysis by P-glycoprotein. J. Biol. Chem. 2003;278:52629–52640. doi: 10.1074/jbc.M308175200. [DOI] [PubMed] [Google Scholar]
  • 51.Omote H, Al-Shawi MK. A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein. J. Biol. Chem. 2002;277:45688–45694. doi: 10.1074/jbc.M206479200. [DOI] [PubMed] [Google Scholar]
  • 52.Horovitz A, Fridmann Y, Kafri G, Yifrach O. Allostery in chaperonins. J. Struct. Biol. 2001;135:104–114. doi: 10.1006/jsbi.2001.4377. [DOI] [PubMed] [Google Scholar]
  • 53.Gallager, R. G. Stochastic processes: theory for applications (Cambridge University Press 2013).

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Peer Review File (329.8KB, pdf)

Data Availability Statement

Data supporting the findings of this manuscript are available from the corresponding author upon reasonable request.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES